Business
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
Webcast to be held Monday, Mar. 20, 4:30 p.m. ET, register here, or at the link below. DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nWebcast to be held Monday, Mar. 20, 4:30 p.m. ET, register here, or at the link below.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its fourth quarter and fiscal year 2022 financial results webcast on Monday, March 20, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.\n\nManagement intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2022 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.\n\nTo register for the webcast, sign up at the link below: https://us06web.zoom.us/webinar/register/3616775268267/WN_94qgn_1IRnuRALmciLu0CQ.\n\nA replay of the webcast will be available after the call on the investor relations section of the Company's website at ir.lanternpharma.com.\n\nAbout Lantern Pharma\nLantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.\n\nPlease find more information at:\nWebsite: www.lanternpharma.com\nLinkedIn: https://www.linkedin.com/company/lanternpharma/\nTwitter: @lanternpharma\nLantern’s Monthly Newsletter – SPARK: Sign-up here\n\nForward-looking Statements:\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populati...